Rheumatology

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Mercy Expands Primary & Specialty Care Network with New Community Physician site in Ellicott City

Retrieved on: 
Tuesday, March 12, 2024
Community, Growth, Sister, Mercy Hospital, Cardiology, Physician, Patient, Foot, Elective surgery, Baltimore metropolitan area, The Sisters of Mercy, Maryland School, University, Left, Ankle, Neurosurgery, Suite, Oella, Maryland, Gynaecology, Sisters of Mercy, Spine, Pain, Multimedia, Catholic Church, Rheumatology, Sports medicine, Nursing

BALTIMORE, Md., March 12, 2024 /PRNewswire-PRWeb/ -- As part of Mercy Health Services' ongoing efforts to expand the reach of the 149-year Sisters of Mercy tradition of quality health care, Mercy has officially opened Mercy Personal Physicians at Ellicott City. Located at 3290 N. Ridge Road, Suite 220, 2nd floor, Mercy Personal Physicians at Ellicott City is a comprehensive, one-stop, medical facility featuring primary care, specialized physician care, and a variety of diagnostic and laboratory services.

Key Points: 
  • As part of Mercy Health Services' ongoing efforts to expand the reach of the 149-year Sisters of Mercy tradition of quality health care, Mercy has officially opened Mercy Personal Physicians at Ellicott City.
  • BALTIMORE, Md., March 12, 2024 /PRNewswire-PRWeb/ -- As part of Mercy Health Services' ongoing efforts to expand the reach of the 149-year Sisters of Mercy tradition of quality health care, Mercy has officially opened Mercy Personal Physicians at Ellicott City.
  • Located at 3290 N. Ridge Road, Suite 220, 2nd floor, Mercy Personal Physicians at Ellicott City is a comprehensive, one-stop, medical facility featuring primary care, specialized physician care, and a variety of diagnostic and laboratory services.
  • Editor's Note: Maryland Family Care is the medical group practice which employs primary care physicians in the Mercy Personal Physicians network.

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
Monday, March 11, 2024
MACR, Psoriatic arthritis, 1991 World Sportscar Championship, INC, Doctor of Philosophy, LOS, MD, SLRN, ISR, Rheumatology, Skin, Safety, Joint, Swedish Health Services, Enthesitis, Patient, Medicine, HS, LEI, Phase, IL-17A

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”

medac unveils new Global Corporate Brand

Retrieved on: 
Monday, March 11, 2024
Therapy, Medac, Health, Rheumatology, Urology, Hematology, Growth, Language, Organization, Pharmaceutical industry

After decades of impressive and successful growth, the company is now unveiling a new global brand to express the transformation as a global player and to extent global impact.

Key Points: 
  • After decades of impressive and successful growth, the company is now unveiling a new global brand to express the transformation as a global player and to extent global impact.
  • The newly established unified brand reflects medac’s commitment to excellence and its global reach, consolidating its position as a key player in the pharmaceutical industry.
  • With a new global brand positioning and design, the brand aims to pursue medac’s promises, such as customer proximity and high expertise.
  • The new brand identity is reflected in a new global corporate website, accessible at www.medac-group.com.

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the Fir

Retrieved on: 
Tuesday, March 5, 2024
PALO, Chronic kidney disease, Rheumatology, Toxicity, ACR, Diarrhea, FDA, Colchicine, Gout, Pharmacy, Risk, Migraine, Health care, Chronic pain, American College, Patient, Pharmaceutical industry

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Key Points: 
  • Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1.
  • These patients may benefit from flexible dosing offered by Gloperba®4
    Scilex plans to launch Gloperba® in the first half of 2024 with a launch price of $595 per 150ml bottle of liquid colchicine formulation.
  • Gloperba is the only FDA approved liquid formulation of colchicine for the prophylaxis of acute gout flares.

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Retrieved on: 
Thursday, February 29, 2024
MIRA, Psoriatic arthritis, EMA, Research, VELA, Medical college, Inflammation, FDA, Investment, Assessment, Conference, AAD, Rheumatology, Event, ARGO, Hidradenitis suppurativa, Webcast, Patient, Science, American Academy, Pharmaceutical industry

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2023 was another momentous year for MoonLake in the inflammation and immunology field.
  • On top of this, support from world-renowned experts, clinicians, and patient organizations for our data, science and methodologies continues to mount.
  • Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics, said: “MoonLake has added considerable shareholder value over the past year, and we are driven to continue building on this.
  • Other non-operating income increased from $0.6 million in the prior year to $10.1 million for the year ended December 31, 2023.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, February 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.

Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market

Retrieved on: 
Friday, February 23, 2024
Therapy, Rheumatology, Rheumatoid arthritis, Physician, Rituximab, Adalimumab, JAK, Health, Patient, MOA, TNF, Research, Pharmaceutical industry

As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.

Key Points: 
  • As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.
  • Ongoing research from Spherix Global Insight’s Patient Chart Dynamix™: Rheumatoid Arthritis (US) service, marking its eighth year of tracking the US RA switch market, sheds light on these key treatment trends and leading opportunities for drug manufacturers.
  • While “TNF cycling” remains common, accounting for about one-third of all switches, this trend has been declining since 2017.
  • Brands that excel in these areas are well-positioned to capture market share and reshape treatment approaches.

Global Healthy Living Foundation Announces irAE Consortium to Address Immune-Related Adverse Events in Cancer Immunotherapy Patients

Retrieved on: 
Monday, March 4, 2024
Oncology, Health, Managed Care, Research, Science, Biotechnology, Caregiver, MD, Immunotherapy, Consortium, Hope, Rheumatology, Patient, Duke University, Patient safety, MD Anderson Cancer Center, Medical Center, Massachusetts General Hospital, Cancer, Pharmaceutical industry

The nonprofit Global Healthy Living Foundation (GHLF) announced its collaboration as a co-founding member of the irAE Consortium, a newly formed collaborative effort uniting clinicians, researchers, and patients to tackle a critical issue facing cancer patients undergoing immunotherapy treatment: adverse reactions.

Key Points: 
  • The nonprofit Global Healthy Living Foundation (GHLF) announced its collaboration as a co-founding member of the irAE Consortium, a newly formed collaborative effort uniting clinicians, researchers, and patients to tackle a critical issue facing cancer patients undergoing immunotherapy treatment: adverse reactions.
  • The inaugural meeting of the Immune-Related Adverse Events (irAE) Consortium is scheduled for March 7-8, 2024, at the Cleveland Clinic in Ohio.
  • This initiative aims to address the unmet needs of cancer patients who experience adverse reactions to immunotherapy, a novel treatment approach.
  • Immunotherapy has revolutionized cancer treatment, offering new hope to patients by harnessing the body’s immune system to fight cancer.